Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Reverse transcriptase inhibitor Stories

2014-02-19 11:04:05

Pittsburgh researchers show how therapy-induced resistance to 'NNRTI' drugs works at 58th Annual Biophysical Society Meeting in San Francisco For the more than one million people with HIV/AIDS in the United States (and the over 34 million people living with HIV/AIDS around the world), antiretroviral drugs such as efavirenz and other so-called non-nucleoside reverse transcriptase inhibitors (NNRTIs) in combination with other antiretrovirals can be a lifeline, because they slow the progress...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2013-04-17 04:21:53

Patients to benefit from potential for improved efficacy in less commonly used types of ARV therapies and one-pill-daily combination drugs LONDON, April 17, 2013 /PRNewswire/ -- The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market. New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of the European HIV Drugs Market, finds...

2013-03-08 00:40:23

Multi-site study, led by a Miriam Hospital researcher, could change treatment strategy for these patients A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression — the primary goal of HIV therapy — without incorporating the traditional class of HIV medications into their treatment regimen. Karen Tashima, M.D., director of the HIV Clinical Trials Program at The Miriam Hospital, served as study chair. The AIDS Clinical Trials Group...

2013-01-03 08:27:02

BURLINGTON, Mass., Jan. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, from 2011 to 2021, growth in the hepatitis B virus (HBV) drug market will be driven by continued uptake of oral nucleoside/nucleotide analogues, such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread. However, the entry of generic Baraclude in 2015 and 2016 in the United States and Europe,...

2012-11-12 08:28:30

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Michelle Berrey, MD, MPH, has joined the company as Chief Medical Officer. "We are delighted to have Michelle join our leadership team. Dr. Berrey is a seasoned drug developer who has established a strong track record in antivirals, in particular with nucleotide analogs. She joins Chimerix at an important time for the...

2012-09-13 10:54:04

Doctors can improve treatment programs using this knowledge The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers, including MU scientists, found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regiment they prescribe to HIV-infected individuals. “The...

2012-07-24 02:27:54

RESEARCH TRIANGLE PARK, N.C., July 24, 2012 /PRNewswire/ -- Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection. Under the terms of the agreement, Merck receives an exclusive worldwide license and will be responsible for development and commercialization of CMX157, an...

2011-06-29 07:00:29

(Ivanhoe Newswire) -- A class of anti-retroviral drugs commonly used to treat HIV, particularly in Africa and low income countries, can cause premature aging, according to this study. The study shows that the drugs damage DNA in the patient's mitochondria "“ the 'batteries' which power their cells. The findings may explain why HIV-infected people treated with antiretroviral drugs sometimes show advanced signs of frailty and age-associated diseases such as cardiovascular disease and...

d3c7b675812ce2a4aec5038c07dc49bc
2011-06-27 05:50:00

Researchers studying the treatment of AIDS in Africa and other poor regions are finding that the drugs used to combat the disease are causing premature aging and lead to age-related illnesses such as heart disease and dementia, Reuters is reporting. British scientists reported in the journal Nature Genetics that the drugs, known as nucleoside analog reverse-transcriptase inhibitors (NRTIs) damage DNA in the patient's mitochondria -- the "batteries" that power cells. The newer cocktails of...